Live Chat

Los Contratos por diferencia («CFD») son instrumentos complejos que comportan un riesgo elevado de pérdidas rápidas debido al apalancamiento. El 74% de las cuentas de inversores particulares pierde dinero al operar CFD con este proveedor. Debe considerar si comprende el funcionamiento de los CFD y si puede permitirse asumir un riesgo elevado de perder su dinero.

Close

Amgen gráfico en tiempo real

Fundamentales del instrumento

Weekly Search
Weekly
Daily
Fecha Cerrar Cambio Cambio del % Apertura Alto Bajo

Últimas noticias

UK GDP
Dyogenes Diniz 2024 Dec 19, 16:00

Adelanto semanal: Última semana completa de 2024 en los mercados financieros

Índices Forex
US interest rate and Europe inflation to guide market direction
Markets.com Support Team 2024 Dec 13, 22:00

Adelanto semanal: Tasas en EE. UU. e inflación en Europa determinarán el curso del mercado

Forex Índices
Dyogenes Diniz 2024 Dec 05, 16:00

Adelanto semanal: La inflación y las tasas de interés sacudirán los mercados esta semana

Forex Índices
US Employment Rate
Markets.com Support Team 2024 Nov 28, 17:00

Adelanto semanal:  El empleo en EE. UU. marcará probablemente el sentimiento de mercado esta semana.

Forex Índices
Eurozone inflation
Markets.com Support Team 2024 Nov 23, 16:00

Adelanto semanal:  Inflación de la Eurozona podría confirmar el recorte del BCE en diciembre

Forex Índices
Nvidia Blackwell AI Chips
Markets.com Support Team 2024 Nov 14, 16:00

Adelanto semanal: El rally tecnológico dependerá de los resultados de Nvidia

Forex Índices
Markets.com Support Team 2024 Nov 07, 16:00

Adelanto semanal: «Trump Trade», datos de inflación, resultados de Disney

Forex Índices
US Election 2024, Harris vs Trump
Markets.com Support Team 2024 Oct 31, 16:00

Adelanto semanal: Trump vs Harris - Enfrentamiento electoral en EE. UU.

Forex Índices

Información

Spread

1.83

Spread (%)

0.6972 %

Apalancamiento

1:5

Interés a un día (Compra)

-0.0597 %

Interés a un día (Venta)

-0.0292 %

Divisa

USD

Horarios de los mercados

Markets closed

Lunes

14:31 - 20:59

Martes

14:31-17:59

Jueves

14:31-20:59

Viernes

14:31-20:59

Análisis y estadísticas

Apertura

---

Cierre anterior

---

Máximo/mínimo de 52 semanas

--- – ---

Capitalización de mercado

141575438336

Acciones en circulación

537532992

Fecha de ganancias (próxima)

1999-11-22

Rentabilidad por div. 

2025-03-07

Fecha exdividendo

2025-02-14

Tasa de dividendo anual anticipado

9.52

Rendimiento de dividendo anual anticipado

0.0361

GPA

7.82

Conoce más sobre este instrumento

Amgen Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Instrumentos relacionados

Activo
Vender
Comprar
Cambio del %
Instrumentos relacionados
Trustpilot
Live Chat